These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15815191)

  • 21. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a role for chemotherapy in prostate cancer?
    Canil CM; Tannock IF
    Br J Cancer; 2004 Sep; 91(6):1005-11. PubMed ID: 15150548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy for prostate cancer].
    Medioni J; Dionysopoulos D; Banu E; Scotté F; Beuzeboc P; Oudard S
    Presse Med; 2008 May; 37(5 Pt 2):814-20. PubMed ID: 18160251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
    Logothetis CJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Docetaxel and prostate cancer].
    Ferrero JM
    Bull Cancer; 2004 Feb; 91(2):172-7. PubMed ID: 15047457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
    DeGrendele H
    Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878
    [No Abstract]   [Full Text] [Related]  

  • 30. What next after hormonotherapy in cancer prostate?
    Parvez T; Al-sisi H; Ibraheim I
    J Coll Physicians Surg Pak; 2003 Oct; 13(10):606-10. PubMed ID: 14588180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing perspectives of the role of chemotherapy in advanced prostate cancer.
    Burgess EF; Roth BJ
    Urol Clin North Am; 2006 May; 33(2):227-36, vii. PubMed ID: 16631461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress in management of advanced prostate cancer.
    Kantoff P
    Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
    Eisenberger MA; Antonarakis ES
    Urol Clin North Am; 2012 Nov; 39(4):573-81. PubMed ID: 23084532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
    Culine S; Droz JP
    Ann Oncol; 2000 Dec; 11(12):1523-30. PubMed ID: 11205458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current indications for chemotherapy in prostate cancer patients.
    Calabrò F; Sternberg CN
    Eur Urol; 2007 Jan; 51(1):17-26. PubMed ID: 17007996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.